Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
暂无分享,去创建一个
Marie-Cécile Le Deley | Charles Ferté | Philippe Vielh | Cécile Jovelet | Thierry De Baere | Fabrice André | Gilles Vassal | Jean-Yves Scoazec | Christophe Massard | C. Lefebvre | A. Eggermont | T. de Baère | F. André | G. Vassal | J. Soria | J. Scoazec | N. Droin | P. Vielh | L. Lacroix | S. Rosellini | C. Ferté | M. Deloger | A. Hollebecque | S. Postel-Vinay | C. Massard | M. Le Deley | Jean-Charles Soria | Ludovic Lacroix | Alexander Eggermont | Ecaterina Ileana | Nelly Motté | Silvia Rosellini | Alfredo Romero | Celine Lefebvre | Marion Pedrero | Noémie Pata-Merci | Nathalie Droin | Marc Deloger | Antoine Hollebecque | Amélie Boichard | Sophie Postel-Vinay | Maud Ngo-Camus | A. Boichard | N. Pata-Merci | Marion Pedrero | M. Ngo-Camus | C. Jovelet | E. Ileana | N. Motté | A. Romero
[1] H. Akaike. A new look at the statistical model identification , 1974 .
[2] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[3] David W. Hosmer,et al. Applied Logistic Regression , 1991 .
[4] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[5] David Olmos,et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Fabrice Andre,et al. Implications of personalized medicine—perspective from a cancer center , 2011, Nature Reviews Clinical Oncology.
[8] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[9] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[10] U. Banerji,et al. Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers , 2012, PloS one.
[11] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[12] N. Rosenfeld,et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.
[13] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[14] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[15] Jorge S. Reis-Filho,et al. Going with the Flow: From Circulating Tumor Cells to DNA , 2013, Science Translational Medicine.
[16] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[17] F. Nicolantonio,et al. Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.
[18] J. Vadgama,et al. The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients , 2013, International journal of molecular sciences.
[19] Carlos Caldas,et al. The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.
[20] N. McGranahan,et al. The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.
[21] Nicolai J. Birkbak,et al. Computational optimisation of targeted DNA sequencing for cancer detection , 2013, Scientific Reports.
[22] F. André,et al. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? , 2014, The Journal of pathology.
[23] C. Paweletz,et al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. , 2014, Journal of the National Cancer Institute.
[24] C. Paweletz,et al. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.
[25] L. Guerra,et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. , 2014, Journal of the National Cancer Institute.
[26] S Michiels,et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[28] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Girard,et al. Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 , 2014, Clinical Cancer Research.
[30] A. Eggermont,et al. Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients , 2014 .
[31] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[32] N. Tunariu,et al. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.
[33] I. Bièche,et al. Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.
[34] A. Bardia. O3.1Targeting the estrogen receptor: old receptor, new drug(s) , 2015 .
[35] C. Massard. O3.7Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 , 2015 .